Anixa Biosciences (ANIX) Notes Payables (2013 - 2014)
Anixa Biosciences' (ANIX) quarterly Notes Payables came in at $1.0 million in Q4 2014, up 91.11% on a YoY basis from $540000.0 in Q4 2013, and down 79.36% quarter-over-quarter from $5.0 million in Q3 2014.
Powered by 
Analysis
Anixa Biosciences (ANIX) Notes Payables (2013 - 2014) Analysis & Trends
Anixa Biosciences (ANIX) has reported Notes Payables for 2 consecutive years, with $1.0 million the latest figure, recorded in Q4 2014.
- For the quarter ending Q4 2014, Notes Payables rose 91.11% year-over-year to $1.0 million; the trailing twelve-month figure through Oct 2014 stood at $1.0 million (up 91.11% YoY), and the FY2014 full-year result was $1.0 million, up 91.11% from the prior year.
- Notes Payables retreated to $1.0 million in Q4 2014 per ANIX's latest filing, from $5.0 million in the prior quarter.
- Across five years, Notes Payables topped out at $5.0 million in Q1 2014 and bottomed at $540000.0 in Q4 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn |
| 10 | Anixa Biosciences | 92.04 Mn | 92.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Oct 31, 2014 | 1.03 Mn |
| Jul 31, 2014 | 5.00 Mn |
| Apr 30, 2014 | 5.00 Mn |
| Jan 31, 2014 | 5.00 Mn |
| Oct 31, 2013 | 540,000.00 |
| Jul 31, 2013 | 700,000.00 |
| Apr 30, 2013 | 970,000.00 |
| Jan 31, 2013 | 1.18 Mn |